Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Zai Lab Ltd ( (HK:9688) ).
Zai Lab has scheduled a board meeting for March 26–27, 2026, to consider and approve its annual results for the year ended December 31, 2025, prepared in accordance with Hong Kong listing rules. The board will also approve the publication of these results for its Hong Kong shareholders and market.
The Hong Kong annual results will align with the 2025 figures already filed with the U.S. SEC under U.S. GAAP, with differences limited to additional disclosures required by Hong Kong rules and a reconciliation to IFRS. This step underscores Zai Lab’s dual‑reporting obligations and may enhance transparency and comparability for global investors across regulatory regimes.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company listed in Hong Kong and incorporated in the Cayman Islands, focused on developing and commercializing innovative medicines. The company operates through subsidiaries and is subject to both Hong Kong listing requirements and U.S. securities regulations, reflecting a cross-border capital markets presence.
YTD Price Performance: 4.76%
Average Trading Volume: 10,192,278
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.1B
See more data about 9688 stock on TipRanks’ Stock Analysis page.